- Home
- AGIO vs SDRL Comparison
AGIO vs SDRL Comparison
Compare AGIO & SDRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- SDRL
- Stock Information
- Founded
- AGIO 2007
- SDRL 2005
- Country
- AGIO United States
- SDRL Bermuda
- Employees
- AGIO N/A
- SDRL N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- SDRL Oil & Gas Production
- Sector
- AGIO Health Care
- SDRL Energy
- Exchange
- AGIO Nasdaq
- SDRL Nasdaq
- Market Cap
- AGIO 1.4B
- SDRL 1.6B
- IPO Year
- AGIO 2013
- SDRL N/A
- Fundamental
- Price
- AGIO $39.05
- SDRL $30.50
- Analyst Decision
- AGIO Buy
- SDRL Strong Buy
- Analyst Count
- AGIO 6
- SDRL 5
- Target Price
- AGIO $58.60
- SDRL $56.50
- AVG Volume (30 Days)
- AGIO 602.7K
- SDRL 1.4M
- Earning Date
- AGIO 07-31-2025
- SDRL 08-06-2025
- Dividend Yield
- AGIO N/A
- SDRL N/A
- EPS Growth
- AGIO N/A
- SDRL 37.29
- EPS
- AGIO 11.45
- SDRL 5.56
- Revenue
- AGIO $37,035,000.00
- SDRL $1,288,000,000.00
- Revenue This Year
- AGIO $22.30
- SDRL $3.80
- Revenue Next Year
- AGIO $219.19
- SDRL $5.71
- P/E Ratio
- AGIO $3.45
- SDRL $5.56
- Revenue Growth
- AGIO 25.96
- SDRL N/A
- 52 Week Low
- AGIO $23.42
- SDRL $17.74
- 52 Week High
- AGIO $62.58
- SDRL $56.46
- Technical
- Relative Strength Index (RSI)
- AGIO 70.00
- SDRL 70.13
- Support Level
- AGIO $34.60
- SDRL $28.57
- Resistance Level
- AGIO $40.06
- SDRL $31.73
- Average True Range (ATR)
- AGIO 1.49
- SDRL 1.09
- MACD
- AGIO 0.43
- SDRL 0.26
- Stochastic Oscillator
- AGIO 86.59
- SDRL 80.34
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.